Jyseleca (Filgotinib)

Filgotinib selectively blocks Janus kinase 1 (JAK1), an enzyme that transmits signals from inflammatory cytokines to the cell nucleus. By inhibiting JAK1, the drug dampens the JAK‑STAT pathway, decreasing the production of inflammatory mediators and thereby reducing joint and intestinal inflammation.

The specific dose of Jyseleca is determined by the prescribing healthcare professional based on the patient’s condition, disease severity, and individual response. Dosage adjustments may be needed for renal or hepatic impairment, and the prescriber will provide detailed instructions.

Safety data for filgotinib in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Women of childbearing potential should discuss contraception and risk with their healthcare provider.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity of Jyseleca. GNH India works with hospitals, pharmacies, and procurement teams worldwide, confirming trade or institutional credentials before providing pricing, availability, shipping details, and any necessary import documentation.

Jyseleca (filgotinib) is a selective JAK1 inhibitor, offering a more targeted approach compared with non‑selective JAK inhibitors that affect multiple JAK isoforms. This selectivity may translate into a different safety profile, but clinical decisions should consider efficacy, tolerability, patient history, and guideline recommendations.

Jyseleca should be stored at room temperature, below 25 °C, in its original packaging to protect it from moisture and excessive light. Keep the product out of reach of children and do not store in bathrooms or other humid environments.

Jyseleca is taken orally, usually as a tablet swallowed whole with water. It is typically administered once daily, but the exact schedule and any food considerations are determined by the prescribing clinician.

Serious risks include opportunistic infections, thromboembolic events such as deep‑vein thrombosis or pulmonary embolism, potential malignancies, severe liver injury, and significant reductions in blood cell counts. Patients should be monitored regularly for signs of infection, clotting, liver dysfunction, and hematologic changes.

Jyseleca is contraindicated in patients with active serious infections, known hypersensitivity to filgotinib or any excipients, and those receiving live vaccines. Caution is advised for individuals with severe hepatic impairment, uncontrolled cardiovascular disease, or a history of malignancy, and the drug should be avoided unless benefits clearly outweigh risks.